Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (151-160 of 432) with videos related to

Pageof 44
Sort By:
Haematologica|January 29, 2026
Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomideWala Najar, Lauren Barette, Dominique Penther, et al.
Leukemia & Lymphoma|March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
Leukemia Research|February 5, 2010
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies)Christian Rose, Sabine Brechignac, Dominique Vassilief, et al.
British Journal of Haematology|December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmStéphane De Botton, Christian Récher, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failureThomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Leukemia Research|December 3, 2014
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failureSylvain Thepot, Simone Boehrer, Valérie Seegers, et al.
Leukemia Research|November 8, 2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidineMarie Sébert, Rami S Komrokji, Mikkael A Sekeres, et al.
Cancer|April 8, 2014
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopeniaAristoteles Giagounidis, Ghulam J Mufti, Pierre Fenaux, et al.
Nature Communications|May 26, 2018
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemiaJacqueline Lehmann-Che, Cécile Bally, Eric Letouzé, et al.
JCO Clinical Cancer Informatics|May 9, 2024
Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and MicrosimulationCaterina Gregorio, Marta Spreafico, Saverio D'Amico, et al.
Pageof 44

Showing results (151-160 of 432) with videos related to

Sort By:
Pageof 44
Haematologica|January 29, 2026
Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomideWala Najar, Lauren Barette, Dominique Penther, et al.
Leukemia & Lymphoma|March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
Leukemia Research|February 5, 2010
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies)Christian Rose, Sabine Brechignac, Dominique Vassilief, et al.
British Journal of Haematology|December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmStéphane De Botton, Christian Récher, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failureThomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Leukemia Research|December 3, 2014
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failureSylvain Thepot, Simone Boehrer, Valérie Seegers, et al.
Leukemia Research|November 8, 2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidineMarie Sébert, Rami S Komrokji, Mikkael A Sekeres, et al.
Cancer|April 8, 2014
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopeniaAristoteles Giagounidis, Ghulam J Mufti, Pierre Fenaux, et al.
Nature Communications|May 26, 2018
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemiaJacqueline Lehmann-Che, Cécile Bally, Eric Letouzé, et al.
JCO Clinical Cancer Informatics|May 9, 2024
Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and MicrosimulationCaterina Gregorio, Marta Spreafico, Saverio D'Amico, et al.
Pageof 44